The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of presumed germline pathogenic variants of hereditary breast cancer predisposition genes in circulating tumor DNA: SCRUM-Japan MONSTAR-SCREEN.
 
Masaya Hattori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; MSD K.K; Pfizer
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Chugai Pharma; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Lilly; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Lilly; Pfizer; Taiho Pharmaceutical
 
Takashi Yamanaka
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Rikiya Nakamura
No Relationships to Disclose
 
Junichiro Watanabe
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai
 
Tetsuhiro Yoshinami
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin International; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo
 
Takao Fujisawa
Honoraria - Merck Serono
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Rui Yamaguchi
No Relationships to Disclose
 
Issei Imoto
No Relationships to Disclose
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)